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Gender differences in the implementation of
cardiovascular prevention measures after an acute
coronary event
Jean Dallongevillle,1 Dirk De Bacquer,2 Jan Heidrich,3 Guy De Backer,2
Christoph Prugger,3 Kornelia Kotseva,4 Miche`le Montaye,1 Philippe Amouyel,1
on behalf of the EUROASPIRE Study Group
ABSTRACT
Objective To compare gender-related lifestyle changes
and risk factor management after hospitalisation for
a coronary event or revascularisation intervention in
Europe.
Method The EUROASPIRE III survey was carried out in 22
European countries in 2006e2007. Consecutive patients
having had a coronary event or revascularisation before
the age of 80 were identified. A total of 8966 patients
(25.3% women) were interviewed and underwent clinical
and biochemical tests at least 6 months after hospital
admission. Trends in cardiovascular risk management
were assessed on the basis of the 1994e1995,
1999e2000 and 2006e2007 EUROASPIRE surveys.
Results Female survey participants were generally older
and had a lower educational level than male participants
(p<0.0001). The prevalences of obesity (p<0.0001),
high blood pressure (BP) (p¼0.001), elevated low-
density lipoprotein (LDL)-cholesterol (p<0.0001) and
diabetes (p<0.0001) were significantly higher in women
than in men, whereas current smoking (p<0.0001) was
significantly more common in men. The use of
antihypertensive and antidiabetic drugs (but not that of
other drugs) was more common in women than in men.
However, BP (p<0.0001), LDL-cholesterol (p<0.0001)
and HbA1c (p<0.0001) targets were less often achieved
in women than in men. Between 1994 and 2007,
cholesterol control improved less in women than in men
(interaction: p¼0.009), whereas trends in BP control
(p¼0.32) and glycaemia (p¼0.36) were similar for both
genders.
Conclusion The EUROASPIRE III results show that
despite similarities in medication exposure, women are
less likely than men to achieve BP, LDL-cholesterol and
HbA1c targets after a coronary event. This gap did not
appear to narrow between 1994 and 2007.
INTRODUCTION
Coronary heart disease mortality rates are lower in
women than in men. They start to increase at the
age of 40 years in men and approximately 10 years
later in women.1 2 In contrast, during and imme-
diately after a coronary event or a percutaneous
transluminal coronary angioplasty (PTCA),
mortality is higher in women than in men.3e8 This
difference is especially marked in younger patients
and tends to narrow with age. However, the long-
term outcome after a myocardial infarction (MI) is
still worse in elderly women than men and narrows
women’s survival advantage over men.6
Several hypotheses may explain the excess
mortality in women after an acute MI (see Shae et al9
for review). First, from an anatomical point of view,
the female vascular bed is smaller and less
compliant, which increases the risk of complica-
tions.10 Second, the symptomatology of cardiac
ischaemia is more often ambiguous and may lead to
a delay in receiving appropriate care.11 12 Third,
comorbidities are more common in women than in
men presenting with a ﬁrst MI and thus result in
worse functional status.8 13e15 Lastly, less intense
management in women during the immediate post-
MI phase has been reported16 but has not been
conﬁrmed in the most recent studies.17e19
There is now ample evidence from observational
epidemiological surveys and randomised controlled
trials that appropriate lifestyles and pharmacolog-
ical treatment can prevent recurrent events and
improve survival in patients with established
coronary heart disease (CHD).20 21 The EURO-
ASPIRE programme is a multicentre European
survey which aims at assessing how the clinical
guidelines on cardiovascular disease prevention are
implemented in daily practice in European coun-
tries. Data of interest were collected directly in
patient interviews and clinical examination by
trained staff according to standardised procedures.
The results of the EUROASPIRE programme have
revealed adverse lifestyle trends in patients with
CHD and a failure to achieve recommended thera-
peutic targets.22e26
In order to better understand the gender differ-
ences in mortality that may occur after a coronary
event, we hypothesised that CHD management
might differ inwomen andmen after hospitalisation
for a coronary event or revascularisation interven-
tion.The extent towhich therapeutic targets aremet
in each gender has not been clearly established.
Therefore, the goal of this study was to compare
cardiovascular disease management in men and
women at least 6 months after hospitalisation for
a coronary event or a revascularisation intervention.
One of the advantages of this strategy is that all
patients went through the cardiology wards and
should receive similar high-standard management of
their disease, no matter what their gender or age.
Based on the results of EUROASPIRE I, II and III, we
also looked at whether patient management and
achievement of therapeutic targets has changed over
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time (between 1994 and 2007) in the same way in men and
women in the eight countrieswhich have participated in the three
surveys.
METHODS
The details of the study protocol are reported elsewhere.25
Brieﬂy, EUROASPIRE III was performed in 2006e7 in 22 Euro-
pean countries. Within each country, one or more geographical
areas with a deﬁned population were selected and all hospitals
serving this population were identiﬁed. A sample of one or more
hospitals, or all hospitals, was taken so that any patient
presenting within the area with acute symptoms of coronary
disease, or requiring revascularisation had an approximately
equal chance of being included. Patients admitted to a hospital
outside this geographical area were not included in the sample.
Within each hospital, consecutive patients (men and women
$18 years and <80 years of age at the time of identiﬁcation,
with ﬁrst or recurrent diagnosis or treatments for CHDdsee
below) were identiﬁed retrospectively from diagnostic registers,
hospital discharge lists or other sources. Patients had to fulﬁl one
or more of the following diagnostic criteria: (i) coronary artery
bypass graft; (ii) PTCA; (iii) MI; (iv) acute myocardial ischaemia
but no evidence of MI (unstable angina) at least 6 months and
not more than 3 years before the expected interview date.
Data were collected by trained research staff who interviewed
and examined the patients at hospital or at home using stand-
ardised procedures and instruments. The following information
was obtained in the interview: personal and demographic
details; personal cardiovascular history (including stroke, tran-
sient ischaemic attacks and peripheral artery disease); other
aspects of the personal medical history, including hypertension,
hyperlipidaemia and diabetes; a family history of CHD for
patients with premature disease (men under 55 and women
under 65); stated lifestyle and other risk factors in relation to
smoking; diet (including weight reduction); exercise; blood
pressure (BP); lipids and glucose; medication (generic names and
the total daily dose); educational level; school attendance and
employment status.
The following measurements were performed: height and
weight in light indoor clothes without shoes (SECA 701 scales
and measuring stick model 220); waist circumference; sitting BP
(measured twice on the right upper arm using an Omron M5-I
automatic digital sphygmomanometer (Omron Healthcare,
Kyoto, Japan)); heart rate and breath carbon monoxide (Micro 4
Smokerlyser, Bedfont Scientiﬁc, Rochester, UK). Venous blood
was tested for serum total cholesterol, high-density lipoprotein
(HDL)-cholesterol, triglycerides, calculated LDL-cholesterol,
plasma glucose and (in patients with diabetes) HbA1c. Obesity
was deﬁned as a body mass index (BMI) $30 kg/m2 and central
obesity was deﬁned as waist girth$102 cm for men and$88 cm
for women. Hypertension was deﬁned as BP$140/90 mm Hg
(or, in diabetic patients, $130/80 mm Hg). Dyslipidaemia was
deﬁned as LDL-cholesterol $2.5 mmol/l or cholesterol
$5 mmol/l. Diabetes was considered to be fasting glycaemia
$7 mmol/l and/or administration of antidiabetic agents.
In order to standardise the measurements taken, all equip-
ment was calibrated and serviced according to the manufac-
turer ’s recommendations. Venous blood samples were handled
and stored according to guidelines prepared by the central
Laboratory of Analytical Biochemistry at the Finnish National
Public Health Institute (Helsinki, Finland). All national coordi-
nators and the main research staff responsible for teaching the
local data collectors were trained at the Coordinating Center at
the Department of Cardiovascular Medicine, National Heart and
Lung Institute, Imperial College London (London, UK).
Although other laboratories were used In EUROASPIRE I and II,
comparisons were made to ensure that the three datasets and
procedures were comparable.
Data management was undertaken at the European Society of
Cardiology Euro Heart Survey Department, European Heart
House (Nice, France). All data were collected electronically using
a unique country, centre and participant identiﬁcation number.
The data were submitted via internet to the data management
centre, where checks for completeness, internal consistency and
accuracy were run. For most variables data are missing for <1%
(see online supplementary table), except blood values due to
logistic reasons and non-fasting; 33% of HbA1c results were
missing. No attempt was made to correct for missing data. The
proportion of missing values did not different between men and
women and hence will not affect our main conclusions. All data
were stored according to the provisions of the national data
protection regulations.
National coordinators were responsible for obtaining approval
from the appropriate local review boards. Written, informed
consent was obtained from each participant by the investigator
by means of a signed declaration. The research assistants signed
the survey’s case report form to conﬁrm that informed consent
had been obtained and then stored the original, signed declara-
tion of consent in the corresponding patient ﬁle.
Trend analysis
For trend analysis, the same geographical areas and hospitals
were used in the countries (the Czech Republic, Finland, France,
Germany, Hungary, Italy, the Netherlands and Slovenia) that
participated in EUROASPIRE I (1994e1995), II (1999e2000)
and III (2006e2007) surveys.25 26 Spain participated in all three
surveys but the investigating centres changed from one survey
to another and so the country was excluded from trend analysis.
Consecutive patients of either gender were identiﬁed as having
undergone revascularisation (coronary artery bypass graft and
PTCA) or having been admitted to hospital with acute MI or
myocardial ischaemia (without enzyme elevation) and were re-
examined at least 6 months later. Since the age at inclusion was
#70 years in the ﬁrst two surveys, our analyses were restricted
to this age class. The overall participation rate was 77.2% in
EUROASPIRE I, 76.5% in EUROASPIRE II and 68.4% in
EUROASPIRE III.
The methods used to ensure comparability of the three
surveys have been speciﬁed elsewhere.25 Brieﬂy, a similar type of
scale was used for each survey and the scales were calibrated at
the start of the surveys. Similar, automatic digital sphygmo-
manometers were used: the Takeda UA 731 (Takeda Medical,
Tokyo, Japan) in EUROASPIRE I, the Omron 711 in EURO-
ASPIRE II and Omron M5-I in EUROASPIRE III. The sphyg-
momanometers’ performance levels were compared and
a correction factor was applied as required. Venous blood was
drawn for measurement of the cholesterol concentration in
plasma (EUROASPIRE I) or serum (EUROASPIRE II and III). A
variety of analysers were used for cholesterol assessment and the
performance levels were compared. As a result, the individual
cholesterol concentrations from EUROASPIRE I were corrected
by a factor of 1.13 for comparative purposes. Plasma glucose
concentrations were measured by a variety of methods in each
survey but these were not standardised for comparison. In
EUROASPIRE I, the plasma glucose concentration was
measured with the hexokinase method on a Technicon Axon
Chemistry Analyser (Miles, Tarrytown, New York, USA). In
Heart 2010;96:1744e1749. doi:10.1136/hrt.2010.196170 1745
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EUROASPIRE II, the plasma glucose concentration was
measured from lithium heparin samples using a hexokinase-
based assay running on a Bayer Axon analyser (Bayer, Lever-
kusen, Germany). The coefﬁcient of variation was 2.8%. In
EUROASPIRE III, plasma glucose was measured in ﬂuoride-
citrate samples with a hexokinase-based assay on a clinical
chemistry analyser (Architect c8000, Abbott Laboratories,
Abbott Park, Illinois, USA). The coefﬁcient of variation was
1.7%.
Statistical analyses
Descriptive statistics were used to estimate the prevalence and
distribution of risk factors and drug use by gender. Risk factor
prevalences for men and women were compared in mixed effects
logistic regression analyses that took account of patient clus-
tering within centres (modelled as a random effect). Age at
interview was modelled as an additional covariate. Gender
differences according to age were evaluated by including an age
(<60 years vs $60 years) by gender interaction term in the
model. The statistical signiﬁcance threshold was set to p¼0.05.
All statistical analyses were performed with SAS software
(version 9.1, SAS Institute, Cary, North Carolina, USA) in the
Department of Public Health, Ghent University (Ghent,
Belgium).
RESULTS
Characteristics of the survey population
A total of 2268 women (25.3%) and 6698 men (74.7%) were
interviewed (table 1). Overall, the women were older and had
a lower educational level than the men and were more likely to
have had acute ischemia as an inclusion criterion. In contrast,
current smoking was more common in men. BMI, obesity,
abdominal obesity, high BP, elevated LDL-cholesterol, HDL-
cholesterol, self-reported diabetes, HbA1c levels and elevated
HbA1c in diabetic subjects were higher in women than in men
independently of age. These associations did not differ when
comparing younger and older patients (ie, statistically signiﬁcant
gender-by-age interactions). In contrast, total diabetes was more
common in women than in men in the under-60s but not in
older patients (interaction p¼0.009).
Medical treatment at interview
The average rate of participation in cardiac rehabilitation
programmes and prescription of antithrombotic drugs and ACE
inhibitors were lower in women than in men (table 2). In
contrast, there were no gender differences in statins and
b-blockers prescription rates. Prescription of other drugsd
namely, angiotensin II receptor blockers, calcium antagonists,
nitrates, diuretics, insulin and oral antidiabetic agents, was more
common in women than in men. These results were homoge-
neous in young and old patients (p>0.1 for all gender-by-age
interaction).
Medical management and achievement of therapeutic targets
Advice for smoking cessation after the acute event and persis-
tence of smoking among former smokers was equally distributed
between men and women (table 3). In obese patients, women
preferred dietary recommendations and men preferred physical
exercise for body weight control. The use of antihypertensive
drugs and antidiabetic agents was more prevalent in women
than in men, as were high BP and high HbA1c levels in treated
patients. Lastly, prescription of hypolipidaemic drugs was
similar in men and women but LDL-cholesterol levels were more
often above target in treated women than in treated men. These
results were homogeneous in young and old patients (p>0.1 for
all gender-by-age interactions).
Trends in risk factors, their management and achievement of
therapeutic targets
Between 1994 and 2007, the prevalence of active smokers
(p¼0.64) and high BP (p¼0.79) remained stable, whereas that of
obesity (p<0.0006) and diabetes (p¼0.004) rose (ﬁgure 1). These
trends were similar for both genders (p>0.1 for all gender-by-
survey interactions). In contrast, raised cholesterol decreased
between 1994 and 2007dan improvement that was less
pronounced in women than in men (interaction: p<0.0001).
Further, interaction testing demonstrated that for both genders,
the trends in the prevalence of smoking (age-by-survey interac-
tion: p¼0.34 and p¼0.80 in men and women, respectively),
obesity (p¼0.46, p¼0.47), high BP (p¼0.76, p¼0.52), diabetes
Table 1 Patient’s characteristics and cardiovascular risk factors at
interview: EUROASPIRE III
Men Women p Valuey
N (%) 6698 (74.7) 2268 (25.3)
Age at interview, mean (SD) 62.2 (9.6) 65.8 (9.0) <0.0001
Index event <0.0001
CABG (%) 20.4 17.2
PTCA (%) 43.5 35.4
AMI (%) 19.1 20.6
Ischaemia (%) 17.0 26.8
Education level <0.0001
Years of school (median) 12.0 11.0
Primary 22.5 33.5
Secondary 39.6 37.0
Intermediate 17.6 17.8
Higher 20.2 11.8
Current smokers (%) 19.3 11.0 <0.0001
BMI (kg/m2), mean (SD) 28.6 (4.2) 29.8 (5.2) <0.0001
Obesity (BMI$30 kg/m2) (%) 32.1 44.7 <0.0001
Waist (cm), mean (SD) 100.8 (11.7) 95.8 (13.6) <0.0001
Central obesity (waist$102/88 cm in
men/women (%)
45.6 73.5 <0.0001
SBP (mm Hg), mean (SD) 139.5 (20.2) 142.5 (22.2) 0.0001
DBP (mm Hg), mean (SD) 82.7 (11.7) 82.9 (12.0) 0.02
Pulse pressure (mm Hg), mean (SD) 56.8 (14.7) 59.6 (16.8) 0.001
Raised BP (BP$140/90 mm Hg) (%) 49.0 54.5 0.001
Raised blood pressure (%)* 80.3 87.9 <0.0001
LDL-cholesterol (mmol/l) 2.7 (0.9) 3.0 (1.1) <0.0001
Raised LDL ($2.5 mmol/l) (%) 52.4 61.1 <0.0001
HDL-cholesterol (mmol/l), mean (SD) 1.1 (0.3) 1.3 (0.3) <0.0001
Fasting triglycerides (mmol/l), mean
(range)
1.4 (1.0e2.0) 1.4 (1.0e1.9) 0.44
Glycaemia (mmol/l), mean (SD) 7.0 (2.1) 7.21 (2.7) 0.02
Self reported diabetes (%) 22.6 30.4 <0.0001
Glycaemia $7 mmol/l) (%) 28.2 29.7 0.55
Total diabetes (%) 33.6 38.4 0.009z
HbA1c in diabetic subjects (%), mean
(SD)
7.1 (1.4) 7.6 (1.7) <0.0001
HbA1c $6.5% in diabetic subjects (%) 61.4 74.1 <0.0001
HbA1c $7% in diabetic subjects (%) 46.1 60.1 <0.0001
Total diabetes: known and/or raised glycaemia.
HbA1C was measured in patients with known diabetes only.
*BP$140/90 or BP$130/80 mm Hg for diabetic patients or treatment for known HTA.
ySignificance between sexes adjusted for age and centre.
zSignificance of the gender-by-age interaction adjusted for centre.
AMI, acute myocardial infarction, BMI, body mass index; BP, blood pressure; CABG,
coronary artery bypass grafting; DBP, diastolic blood pressure; LDL, low-density lipoprotein;
PTCA, percutaneous transluminal coronary angioplasty; SBP, systolic blood pressure.
1746 Heart 2010;96:1744e1749. doi:10.1136/hrt.2010.196170
Epidemiology
 group.bmj.com on October 25, 2010 - Published by heart.bmj.comDownloaded from 
(p¼0.58, p¼0.17) and raised cholesterol (p¼0.07, p¼0.18) did
not differ signiﬁcantly when comparing younger patients
(<60 years) and older patients($60 years).
The prescription of all prophylactic drugs rose between 1994
and 2007 (table 4). This change was similar in men and women
for all drugs except antiplatelet agents, the use of which
increased more quickly in women than in men (interaction:
p¼0.003). Finally, we also looked at whether BP, cholesterol and
glycaemia targets were reached in patients being treated for
these risk factors. Between 1994 and 2007, the extent of BP
control remained stable and that of glycaemia deteriorated.
These latter trends were similar in men and women. In contrast,
cholesterol control improved less in women than in men
(gender-by-time interaction: p¼0.009).
DISCUSSION
The goal of this study was to assess whether the implementa-
tion of demonstrably effective treatments for secondary
prevention and appropriate use (estimated by achievement of
therapeutic targets) were similar in men and women 6 months
after hospitalisation for a coronary event or revascularisation
intervention.
The EUROASPIRE surveys revealed subtle differences in
the management of men and women. Antiplatelet agents and
ACE inhibitors were less frequently prescribed in women than
in men. Similar differences were reported in earlier reports
in North America.9 27 In contrast, statins and b blockers were
prescribed to between 75% and 80% of both men and women,
illustrating the potential for improvement in both genders.
Renineangiotensin inhibitors, nitrates, calcium antagonists,
diuretics and insulin were more frequently prescribed in women
than in men probably in relation to the higher prevalence of
angina and burden of cardiovascular risk factors in women.
Cardiac rehabilitation was less frequently prescribed in women
than in men, but not advice for smoking cessation resulting in
similarly poor control of smoking after hospitalisation. Finally,
women were more likely to change their dietary habits and men
appeared to prefer physical activity to control their excess body
weight, reﬂecting traditional societal patterns.
Of the patients receiving treatment for hypertension, hyper-
cholesterolaemia and diabetes, women were less likely to achieve
and maintain the therapeutic goals. One possible explanation
may be worse titration of drug treatments in the women. In
agreement with this hypothesis, lower use of treatments during
the acute phase of a coronary event has been reported in women,
relative to men.16 This may result in less active care a long time
after a coronary event. Another possible explanation is that
therapeutic targets are harder to attain in women because the
latter have a worse cardiovascular risk proﬁle than men.9 For
instance, women had a higher mean BMI than the men, which
partly explains the greater prevalence of diabetes. Similarly, self-
reported diabetes increased between the three EUROASPIRE
Table 2 Medical treatment after index event at interview:
EUROASPIRE III
Men Women p Value*
Secondary prevention treatment
Aspirin or antiplatelets 91.2 88.3 0.03
b Blockers 79.4 80.8 0.51
Statins 78.9 75.7 0.39
ACE 60.2 59.2 0.01
Angiotensin II receptor antagonist 10.9 15.3 <0.0001
Cardiovascular risk factor treatment
Anticoagulants 5.7 5.4 0.07
Calcium antagonists 22.3 30.7 <0.0001
Nitrates 26.0 34.5 <0.0001
Diuretics 26.4 41.3 <0.0001
Insulin 5.5 8.8 <0.0001
Oral antidiabetic agent 13.6 17.0 0.0003
Results are shown as percentages.
*Significance between sexes adjusted for age and centre.
Table 3 Medical management after index event at interview:
EUROASPIRE III
Men Women p Value*
Cardiac rehabilitation attendancey 34.9 31.0 0.002
Advice given to current smokers
Verbal 91.3 87.7 0.10
Written 34.3 36.7 0.83
Clinic 14.1 15.4 0.67
Smoking among former smokers 51.9 51.9 0.91
Action taken to control excess body weight
Following dietary advice 50.3 55.1 0.04
Regular physical activity 40.3 33.8 0.01
Weight reduction drugs 1.8 2.3 0.31
None 39.2 39.5 0.59
Hypertension
Use of antihypertensive drugs 66.8 80.1 <0.0001
Raised blood pressurez in treated
patientsx
61.3 66.1 0.004
Raised blood pressurez in treated
patients{
54.4 61.0 <0.0001
Dyslipidaemia
Lipid lowering drug use 80.4 77.9 0.83
LDL $ 2.5 mmol/l in treated patients 46.3 54.8 <0.0001
Diabetes
Use of pharmacological treatment 17.3 22.8 <0.0001
Glucose $7 mmol/l in treated patients 78.1 74.4 0.35
HbA1c $7% in treated patients 49.6 63.0 <0.0001
Results are shown as percentages.
*Significance between sexes adjusted for age and centre.
yattending at least half of the sessions.
zBP$140/90 or BP$130/80 mm Hg for diabetic patients or treatment.
xIn patients treated with antihypertensive drugs.
{In patients treated with any drug which may lower blood pressure (but not specifically
prescribed for this reason).
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Figure 1 Trends in risk factors in men and women across the
EUROASPIRE (EA) surveys. EA I: 1994e1995 EUROASPIRE surveys; EA
II: 1999e2000 EUROASPIRE survey; EA III: 2006e2007 EUROASPIRE
survey. The same hospitals from the same geographical areas and
countries (the Czech Republic, Finland, France, Germany, Hungary, Italy,
the Netherlands and Slovenia) that participated in EUROASPIRE I
(1994e1995), II (1999e2000) and III (2006e2007) survey were
included in this analysis. Age at inclusion was # 70 years in the three
surveys. BP, blood pressure; Chol, cholesterol.
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surveys, which reﬂects the rise in obesity. Of particular concern,
this increase over time could be partly explained by the changes
in methodology for measuring glucose, but the direction of
change is consistent with that for self-reported diabetes. Like-
wise, the more frequent use of insulin25 26 in women may reﬂect
more advanced diabetes and thus control of glycaemia. Taken as
a whole, these data highlight shortcomings in control of BP,
LDL-cholesterol and diabetes in women (relative to men) after
hospitalisation for a coronary event or revascularisation inter-
vention. These shortcomings appear to be more related to
suboptimal management of therapeutic targets than a lack of
prescription of pharmacological agents.
Between 1994 and 2007, trends in the prescription of all
cardioprotective drugs (except antiplatelet agents) were similar
in women and men, suggesting that prescription of cardiopro-
tective drugs in the past decade has not been inﬂuenced by
gender. These trends were similar across different categories of
index events. Only antiplatelet treatment was lower in patients
included with ischemia in 1994 but the rates of prescription
increased similarly in men and women. In contrast, the control
of hypercholesterolaemia improved less in women than in men,
further suggesting that the management of certain risk factors
was and remains different between genders. In contrast, BP
control was stable and that of glycaemia worsened to a similar
extent in men and women over the same period of time.
This study has several strengths and limitations. The
EUROASPIRE surveys were carried out in the same geographical
areas and hospitals and using the same protocol. This enables
valid long-term comparisons to be made. Contrary to some
other surveys based on data from medical records18 27 or clinical
trials,8 the patients in all EUROASPIRE centres were examined
by trained staff using standardised methods, which minimised
errors or recall bias. The EUROASPIRE surveys are population
based, which reﬂects the usual medical care of patients in the
community. In contrast, data from randomised clinical trials are
more likely to mask gender differences, in view of the selection
criteria and intensive management of associated comorbidities.
Between 1994 and 2007, the deﬁnition of MI had changed
(especially with the implementation of troponin assays). This
leads to a certain overlap across index event deﬁnitions.8
In conclusion, our results show that after hospitalisation for
a coronary event or intervention, there were no major gender
differences in the pharmacological management of CHD. In
contrast, women achieved the therapeutic targets for BP, LDL-
cholesterol and HbA1c less often than men. These differences
were already noticed in the early 1990s and did not improve
between1994 and2007.TheEUROASPIRE results clearly point to
the potential throughout Europe for raising standards in preven-
tive cardiology, in general, and in female patients, in particular.
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